ArticleOncotarget2017

A ruthenium anticancer compound interacts with histones and impacts differently on epigenetic and death pathways compared to cisplatin.

Cynthia Licona et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.